Skip to main content
OpenTrials
Completed

NCT Number: NCT00394069

PK Study in 3- to 6- Month-Old Children (0476-268)(COMPLETED)

The purpose of this study is to look at the preliminary safety profile of an investigational drug in children 3 to 6 months of age with bronchiolitis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

3 month–6 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Active bronchiolitis or a history of bronchiolitis and asthma-like symptoms

Exclusion criteria

  • A history of any significant illness that will pose additional risk to the patient

Treatment and study plan

MK-0476, montelukast sodium

Drug

Duration of Treatment: 14 Days

Primary outcomes

  1. To evaluate the safety and tolerability of montelukast oral granules in children aged 3 to 6 months.

    Time frame: 14 days

Secondary outcomes

  1. To estimate the single-dose population pharmacokinetics, maximum plasma concentration, time to maximum plasma concentration, and apparent half-life of montelukast 4-mg oral granules in children aged 3 to 6 months.

    Time frame: 24 hours

Sponsors and collaborators

Lead sponsor

Organon and Co

Industry

Registry information

Official study title

A Randomized, 3-Period, Multiple-Dose, Multicenter Study to Evaluate the Safety, Tolerability, and Plasma Concentration Profile of Montelukast Administered Once Daily as Oral Granules in Children Aged 3 to 6 Months

Important dates

Study start
2003
Primary completion
2003
Study completion
2003
First posted
Oct 31, 2006
Registry last updated
Aug 14, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.